The growth of Viagra and its influence on the drug landscape presents a intricate question for investors. While the first sales figures were remarkable, the intellectual property has lapsed, leading to a deluge of generic alternatives that are reducing earnings. In addition, the market is facing challenges related to aging trends and evolving healt